Mesalamine To Reduce Immune Activation During HIV Infection: A Randomized Controlled Trial
Phase of Trial: Phase IV
Latest Information Update: 07 Apr 2014
Price : $35 *
At a glance
- Drugs Mesalazine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 07 Apr 2014 New trial record
- 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
- 04 Mar 2014 Primary endpoint 'CD8+-cell-percentage' has not been met.